Himuka AM Pharma Corp.
About
Himuka AM Pharma Corp. is a multi-asset clinical-stage biopharmaceutical company focused on developing novel treatments in areas of unmet need including refractory Inflammatory bowel disease (IBD) and vascular cognitive impairment (VCI).
Adrenomedullin (AM) has a strong activity to heal colitis with intestinal epithelial barrier stabilization and AM ameliorated colitis both in animal models and human patients. Furthermore, AM development has potential applications in the treatment of CADASIL, a form of cerebral small vessel disease and a model of vascular cognitive impairment.
Himuka’s HM201 which is a pegylated AM showed improved blood stability and safety in the phase 1 study in Australia.
Himuka is seeking a development and/or finance partner to collaborate on a phase 2 study to demonstrate the efficacy of HM-201
Advantages of HM201
-
IBD: Complete mucosal healing remains challenging, and no drugs exist that can promote structural repair of the intestinal mucosa.
-
VCI: Beyond improving cerebral blood flow, improvements in cognitive function can also be expected.
Seeking a development and/or finance partner to collaborate a phase 2 study to demonstrate the efficacy of HM201.
Areas of activity
Business Domain / 分野
Business Type / 業種
Disease Area / 疾患領域
Modalities / モダリティ
Additional information
企業/団体名 (日本語) / Company name in Japanese
ひむかAMファーマ株式会社
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Researched disease area / マッチングご希望の疾患領域
Researched Modality / マッチングご希望のモダリティ
Researched Technologies / マッチングご希望の技術